Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258217 · ClinicalTrials.gov registry record · NA
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)
A NA study of Relapsing Remitting Multiple Sclerosis, sponsored by OhioHealth.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02258217: Completed NA study of Relapsing Remitting Multiple Sclerosis, sponsored by OhioHealth.
NCT02258217 is a NA study of Relapsing Remitting Multiple Sclerosis that has completed, run by OhioHealth. The registered enrollment target is 30 participants, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02258217, a NA study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by OhioHealth.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
Primary Outcome
Patient history of prior corticosteroid tolerability for the treatment of MS relapses. This will be determined based on patient completion of the ARMS survey at the baseline visit. Also, history of patients from the survey after treatment for the new relapse will be collected. The ARMS questionnaire (assessing relapses in multiple sclerosis) was developed by a panel of expert MS nurses. Part one consists of 7 questions designed to assess relapse symptoms, impact on activities of daily living, a
Conditions Studied
Interventions
- DRUG Acthar
Study Locations (1)
Ohio
- OhioHealth - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-12 |
| Phase | NA |
What the finished NCT02258217 record still lists
NCT02258217 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 201-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Acthar is the first listed.
NCT02258217 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02258217 about?
NCT02258217 is a clinical study titled "Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)". Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
What is the current status of trial NCT02258217?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-06. Estimated completion is 2016-12.
What conditions does trial NCT02258217 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
What interventions are being tested in trial NCT02258217?
The interventions under investigation include: Acthar (DRUG).
Who is sponsoring clinical trial NCT02258217?
This trial is sponsored by OhioHealth, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02258217 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02258217's enrollment target sits among peer trials
30 24th of 25 higher than 1 of 25 other Relapsing Remitting Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Remitting Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
-
Development of a Motivational Intervention to Improve Treatment Adherence in MS
COMPLETED · NA
-
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
RECRUITING
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia